298 related articles for article (PubMed ID: 33973053)
1. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
2. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.
Evens AM; Choquet S; Kroll-Desrosiers AR; Jagadeesh D; Smith SM; Morschhauser F; Leblond V; Roy R; Barton B; Gordon LI; Gandhi MK; Dierickx D; Schiff D; Habermann TM; Trappe R
Am J Transplant; 2013 Jun; 13(6):1512-22. PubMed ID: 23721553
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Cavaliere R; Petroni G; Lopes MB; Schiff D;
Cancer; 2010 Feb; 116(4):863-70. PubMed ID: 20052713
[TBL] [Abstract][Full Text] [Related]
4. A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.
Lake W; Chang JE; Kennedy T; Morgan A; Salamat S; Başkaya MK
Neurosurgery; 2013 Jun; 72(6):960-70; discussion 970. PubMed ID: 23685504
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.
Ginat DT; Purakal A; Pytel P
J Neurooncol; 2015 Nov; 125(2):297-305. PubMed ID: 26341369
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
7. Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.
Khedmat H; Taheri S
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):235-42. PubMed ID: 23538344
[TBL] [Abstract][Full Text] [Related]
8. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
9. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
10. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
11. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
12. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
Dugan JP; Haverkos BM; Villagomez L; Martin LK; Lustberg M; Patton J; Martin M; Huang Y; Nuovo G; Yan F; Cavaliere R; Fingeroth J; Kenney SC; Ambinder RF; Lozanski G; Porcu P; Caligiuri MA; Baiocchi RA
Clin Cancer Res; 2018 Jul; 24(14):3273-3281. PubMed ID: 29632007
[No Abstract] [Full Text] [Related]
13. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
14. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
15. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
16. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
17. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
18. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
Major A; Kamdar M
Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
[TBL] [Abstract][Full Text] [Related]
19. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]